Sharemaestro Newsreel

Is Phibro Animal Health (PAHC) Undervalued On Its Dividend Update?

Organigram Global (NASDAQ: OGI) sets Q3 2026 earnings call for Aug. 11

Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality

Haleon PLC Revenue Breakdown – SWB:H6D0

This article provides a revenue breakdown for Haleon PLC (SWB:H6D0). Last year, the company generated €12.65 billion in revenue, with its Oral Health segment contributing the most at €3.97 billion. Geographically, EMEA and Latin America were the largest contributors, accounting for €5.27 billion.

Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets

Evolus, Inc. has expanded its licensing agreement with Symatese Aesthetics to include exclusive commercialization rights for the Estyme® injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This expansion, costing Evolus an upfront payment of €920,000 and potential regulatory milestone payments of up …

Behavioral Patterns of BCRX and Institutional Flows

The article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), highlighting a weak near and mid-term sentiment but a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance …

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma …

Evolus expands hyaluronic acid gel rights to three markets

Evolus Inc. has expanded its licensing and distribution agreement with Symatese to gain exclusive rights for commercializing Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This move adds three new markets to Evolus's hyaluronic acid gel portfolio, with commercialization expected by …

Tilray Brands Posted Record Numbers for Fiscal 2026. Here's Why That's Not Enough to Make the Stock a Buy

Tilray Brands reported record net revenue of $915.5 million for fiscal year 2026, an 11% increase year-over-year. However, the article argues that this growth is primarily driven by costly acquisitions and international expansion, masking a lack of organic growth and leading to significant cash …

Anika Therapeutics Lifts Outlook After Margin Surge

Anika Therapeutics reported strong Q2 earnings, with record commercial and international revenue and significantly improved gross margins and adjusted EBITDA. The company raised its full-year guidance for revenue growth and adjusted EBITDA margin, despite acknowledging regulatory uncertainties for some products and potential quarterly variability …

Farallon Group discloses 8.37M Liquidia (LQDA) shares, a 9.4% ownership stake

Farallon Capital Management, L.L.C. and related entities have disclosed an 8.37 million share beneficial ownership stake in Liquidia Corporation (LQDA), representing 9.4% of the company's outstanding common stock. This information was filed via an amended Schedule 13G/A, indicating shared voting and dispositive power over …

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus, Inc. has expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand. This expansion will complement Evolus' existing neurotoxin offerings (Jeuveau® and Nuceiva®) in these markets, creating …

Viatris declares $0.12 quarterly dividend per share By Investing.com

Viatris Inc. announced that its Board of Directors has declared a quarterly dividend of $0.12 per share. This dividend will be paid to shareholders of record as of August 21, 2026, with the payment date set for September 16, 2026. The announcement was made …

Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook Reveals 8.80% Upside Potential

Amphastar Pharmaceuticals (NASDAQ: AMPH) is a biopharmaceutical company with a diverse product portfolio showing an 8.80% upside potential from its current stock price of $20.22, with an average target price of $22.00. Despite its strong free cash flow and return on equity, caution is …

UBS raises Amneal Pharmaceuticals price target on biosimilar growth

UBS has increased its price target for Amneal Pharmaceuticals Inc. to $25.00 from $23.00, maintaining a Buy rating. This adjustment follows the company's strong second-quarter earnings beat and raised guidance, despite a recent stock pullback. UBS anticipates significant growth from Amneal's biosimilar and generic …

Viatris Announces Quarterly Dividend

Viatris Inc. (Nasdaq: VTRS) announced that its Board of Directors declared a quarterly dividend of $0.12 per share. The dividend is payable on September 16, 2026, to shareholders of record as of August 21, 2026. The company also included a section on forward-looking statements …

Bausch Health Companies Inc. (BHC) Stock Analysis: Uncovering A 7.14% Upside Potential

Bausch Health Companies Inc. (BHC) is a healthcare company with a diversified portfolio showing a potential upside of 7.14%. Despite mixed valuation metrics and cautious analyst ratings, the company boasts solid revenue growth and substantial free cash flow. Investors are advised to monitor technical …

Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 12.7% in the first quarter, now owning over 2 million shares. Despite this institutional interest, Amphastar's recent quarterly earnings missed analyst expectations for both EPS and revenue, contributing to a "Reduce" …

The Manufacturers Life Insurance Company Sells 155,079 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

The Manufacturers Life Insurance Company reduced its stake in Teva Pharmaceutical Industries Ltd. by 30.8% in Q1 2026, selling 155,079 shares but still holding 348,898 shares valued at $10.5 million. Meanwhile, Teva insiders sold 270,493 shares worth approximately $9.48 million during the last quarter. …

Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum

Teva Pharmaceutical Industries saw its shares rise by 8.8% after it raised its 2026 revenue guidance to US$16.50–US$16.85 billion and affirmed mid-single digit revenue growth targets for 2027. The company's strategy focuses on a shift towards higher-value innovative medicines, driven by strong performance from …

Dr Reddy’s Laboratories launches Sugammadex injection in US

Dr. Reddy’s Laboratories has launched Sugammadex Injection Single-Dose Vials, a generic equivalent of Bridion, in the United States, coinciding with the first day of generic availability. This product is indicated for reversing neuromuscular blockade in adult and pediatric patients undergoing surgery. Bridion, the brand-name …

Organigram to Report Third Quarter Fiscal 2026 Results on August 11, 2026

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) announced it will report its third-quarter fiscal 2026 earnings results on Tuesday, August 11, 2026, before market open. The company, Canada's #1 cannabis company by market share and a growing global cannabis platform, will host a conference …

Optimi Health Corp. Revenue Breakdown – CSE:OPTI

This article provides a brief overview of Optimi Health Corp.'s (CSE:OPTI) revenue breakdown, highlighting that Canada was the primary contributor to its revenue in the last two fiscal years. In the most recent year, Canada accounted for 426.30K CAD, a slight increase from the …

OPTH: A licensed manufacturer already selling MDMA while peers still wait on trials

Optimi Health (NASDAQ: OPTH) is presented as a unique investment opportunity in the psychedelic biotechnology sector, distinguishing itself as a commercial-stage manufacturer of pharmaceutical-grade psilocybin and MDMA, rather than a drug developer reliant on clinical trials. The article highlights Optimi's established licensing, vertical integration, …

Haleon Canada Appoints Daniela Cavinatto as General Manager

Haleon, a global consumer healthcare company, has appointed Daniela Cavinatto as General Manager for its Canadian operations. Cavinatto brings over 25 years of international leadership experience and a strong track record of driving business growth and leading transformations. In her new role, she will …

Amylyx Ongoing Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The firm alleges that Amylyx overstated the …

ALVO|Alvotech SA|Price:3.785|Chg%:-0.335

Alvotech SA (ALVO) has a relatively weak fundamental profile but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have recently rated it as a "Buy" with a target price …

BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?

BioCryst Pharmaceuticals (BCRX) stock has seen a recent decline after a strong year, leading to questions about its valuation. Despite being 58.6% undervalued according to a popular narrative with a fair value of $21.30 against its current $8.81, the company faces pressure points like …

Niagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate

Niagen Bioscience has partnered with Evotec to accelerate the preclinical development of its oral small-molecule candidate, NB4168. This collaboration aims to advance NB4168, intended for the treatment of ataxia telangiectasia (A-T), towards clinical evaluation. Evotec will conduct pharmacokinetic and pharmacodynamic studies to validate bioanalytical …

Q1 2025 Anika Therapeutics Inc Earnings Call Transcript

Anika Therapeutics Inc. (ANIK) reported mixed results for Q1 2025, with commercial channel revenue up 18% and regenerative solutions growing 33%, driven by the Integrity implant system. Strategic initiatives and cost-saving measures proved effective, with anticipated US approvals for Halofast and Singal expected to …

First Trust Advisors LP Cuts Holdings in Elanco Animal Health Incorporated $ELAN

First Trust Advisors LP significantly reduced its stake in Elanco Animal Health Incorporated by 78.1% in the first quarter, selling 827,946 shares. Despite this, other institutional investors like PNC Financial Services Group Inc., KBC Group NV, and Swiss National Bank increased their holdings. Elanco …

Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Large Volume Increase - What's Next?

Viatris (VTRS) Q2 Earnings Report Preview: What To Look For

Zimmer Biomet Deal Closes, Pacira Receives $73.6M Cash

Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates